

ROI

RETURN ON INNOVATION

Ontario Centres of Excellence Inc.

Centre for Commercialization
of Research (CCR)

Annual Report 2010/2011



Ontario Centres of
Excellence

Where Next Happens


Centre for
**Commercialization
of Research (CCR)**

Canada 

OCE's Centre for Commercialization of Research is supported by the federal government through a Networks of Centres of Excellence program.

 Ontario

Ontario Centres of Excellence (OCE) is funded by the Government of Ontario. OCE is a member of the Ontario Network of Excellence (ONE).



(Left to right) John Connolly, VP Corporate Development, Rna Diagnostics and John Jordan, Chief Financial Officer, Rna Diagnostics together with Marc Castel, CCR Regional Commercialization Director and Kenneth P.H. Pritzker MD, President and CEO, Rna Diagnostics.

CENTRE FOR
COMMERCIALIZATION
OF RESEARCH (CCR)

Rna Diagnostics Inc.

Better, faster management of breast cancer treatments

RETURN ON INNOVATION

- 4 new jobs created
- \$500 million market opportunity; Rna plans to address approximately \$100 million of this potential, within the next five to six years

Currently, just 25% of breast cancer patients have a long-term survival benefit from chemotherapy treatments. Recognizing *which* patients are benefiting – and therefore which patients should receive different treatment – has not previously been determinable before the patient completes multiple chemotherapy cycles. Now, Rna Diagnostics Inc. has developed a proprietary test to assess the impact of chemotherapy as early as the middle of the first treatment cycle – a significant improvement that has the potential to speed the switch of the other 75% of patients to more promising treatments, as well as to reduce patient suffering caused by chemotherapy side effects, and reduce the healthcare system’s costs of ineffective treatments.

The Rna disruption assay (RDA) test enables oncologists to examine the molecular structure of a cancerous tumor to determine its response to chemotherapy. Disruption of the tumor’s RNA indicates that the patient is responding positively; unaffected RNA indicates that the chemotherapy is not effective and that the patient’s treatment should be adjusted.

The technology was pioneered by Laurentian University Associate Professor Amadeo Parissenti, with research associate Dr. Baoqing Guo of Sudbury Regional Hospital. Proof of principle was established in a multi-centre clinical trial, based at Sunnybrook Hospital. Ultimately, the technology may be applied to managing treatments for other cancers, other diseases, and assessing drug or chemical toxicities.

OCE’s Centre for Commercialization of Research (CCR) support helped secure the intellectual property underlying the test, as well as negotiating its use through licensing. CCR also played a key role in funding, from initial technology development, to syndicated follow-on equity investment and continuing commercialization. Over the last year Rna Diagnostics has been recognized with first prize in the 2010 Sanofi Pasteur Healthcare & Biotechnology Venture Challenge and received the 2011 TIEQuest, Best Healthcare Industry Award and Best Intellectual Property Award.

OCE’s Centre for Commercialization of Research (CCR)’s financial support has been vital in enabling us to advance this company, both by accelerating our product development, and by helping us attract a further \$1.25 million in follow-on funding from public and private investors.”

Dr. Ken Pritzker, CEO, Rna Diagnostics Inc.